ClinicalTrialsFinder
RecruitingNCT01587300

Neuroblastoma Biology Study

N2004-05: Neuroblastoma Biology Study

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

Enrollment

1,000 participants

Start Date

Jul 1, 2011

Study Type

OBSERVATIONAL

Conditions

Neuroblastoma

Summary

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Eligibility

Min Age: 31 DaysMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting biological samples and data from children with high-risk neuroblastoma — an aggressive childhood cancer that typically starts in the adrenal glands or the nervous system — to help researchers understand the biology of the disease and develop better treatments. **You may be eligible if...** - Your child is more than 31 days old - Your child has been diagnosed with high-risk neuroblastoma, either confirmed by a biopsy or by the presence of cancer cells in the bone marrow along with elevated levels of certain markers in the urine - Your child has relapsed or treatment-resistant high-risk neuroblastoma and is being treated at a participating institution **You may NOT be eligible if...** - Your child is 31 days old or younger - The diagnosis of high-risk neuroblastoma has not been established - Your child is not being seen at one of the participating study sites Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(17)

Children's Hospital Los Angeles

Los Angeles, California, United States

Lucille Salter Packer Children's Hospital, Stanford University

Palo Alto, California, United States

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Children Hospital of Colorado

Aurora, Colorado, United States

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus

Atlanta, Georgia, United States

University of Chicago, Comer Children's Hospital

Chicago, Illinois, United States

Children's Hospital Boston

Boston, Massachusetts, United States

C.S Mott Children's Hospital

Ann Arbor, Michigan, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Nationwide Children's Hospital

Columbus, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

University of Texas Southwestern

Dallas, Texas, United States

Cook Children's Medical Center - Fort Worth

Fort Worth, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

Hospital for Sick Children

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01587300

Related Trials

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT011093945 locations

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

NCT010056541 location

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296178 locations

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

NCT0646519910 locations

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

NCT0645004113 locations